Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms Underlying Hypotensive Response to LCZ696 in Heart Failure
NCT04113109Phase 4Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Nov 2019
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sacubitril + valsartan in heart failure (HF) (4 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Mean Arterial Pressure at 8 hours and Urine Sodium Excretion at 6 hours. Started Nov 2019; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04113109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04113109.